Biology subjects

Tumentemur, G.

Publications and source records attributed to Tumentemur, G..

4 recordsLinked to original sources

bioRxiv2023

The Effect of Amniotic Fluid On Haıir Follicle Growth

Human amniotic fluid stem cell (hAFSC) exhibit significantly as a new treatment modality in hair loss, wound, scar and regenerative plastic surgery/dermatology. The difference of our study from previous amniotic fluid studies on the hair growth model was studied through the direct effect of human amniotic fluid (hAF). In our study, amniotic fluid was made acellular, pooled and freezed, making it more standardized in terms of its contents. Therefore, the present study is aimed at investigating the efficacy and safety of amniotic fluid in hair loss model on rat. Using the hair loss model rats, we investigated the therapeutic potential of freezing amniotic fluid (FAF) and freezing gama irradiated amniotic fluid (FAFI). Our results showed that FAF and especially FAFI increased number of total hair follicles and accelerated number of transition to anagenic hair follicle. We observed that increased rate of arginase+1(Arg+1)/CD68 activity around the hair follicles treated with hAF. Our study suggests that FAFI may represent a safe and effective tool for increasing hair follicle and accelerating to anagen stage during hair loss model.

pathology↗

bioRxiv2023

Effect of Dual Leucine Zipper Kinase Inhibitor GNE-3511 on Epileptogenesis and Cognitive and Behavioral Changes in a Temporal Lobe Epilepsy Model in Mice

Inflammation and neuronal loss are key factors in the pathophysiology of epilepsy. It is known that activation of Dual Leucine Zipper Kinase (DLK) in chronic neurodegenerative diseases causes neuron death and axon degeneration through apoptotic pathways. Genetic deletion of DLK (dual leucine zipper kinase, MAP3K12) or pharmacological inhibition by GNE-3511 or GNE-8505 was found to have benefits in mouse models of Alzheimers and ALS; however, there is no previous study that uses DLK inhibitors in epilepsy models. Therefore, the aim of our study is to suppress the DLK/JNK pathway with the DLK inhibitor GNE-3511 in the temporal lobe epilepsy model induced by pilocarpine and to determine the effect of this inhibition on cognitive and behavioural defects, as well as epileptogenesis. Open field, elevated plus maze, and Morris water maze tests were used to assess locomotor activity, anxiety and learning and memory, respectively. Following decapitation the hippocampi were removed and, histopathological and biochemical analyses were performed. Both treatment groups had less anxiety and locomotor activity as well as decreased impairment in memory and learning performance compared to SE group (p<0.001). Both doses of GNE-3511 prevented the spontaneous recurrent seizures in a dose dependent manner with respect to the SE group (p<0.01 and p<0.001, respectively). Histological examination of the hippocampus revealed a neuroprotective effect of both doses of treatment in the CA1 area and dentate gyrus (p<0.0001). Thus, DLK inhibitor GNE-3511 was found to be effective in preventing epileptogenesis, neuronal loss and cognitive and behavioural deficits due to pilocarpine induced SE.

neuroscience↗

bioRxiv2020

Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice

The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A, oral polio vaccine, and smallpox proved to be reliable approaches for immunization for prolonged periods. During the pandemic, we produced an inactivated SARS-CoV-2 vaccine candidate, having the advantages of being manufactured rapidly and tested easily in comparison with recombinant vaccines. In this study, an inactivated virus vaccine that includes a gamma irradiation process for the inactivation as an alternative to classical chemical inactivation methods so that there is no extra purification required has been optimized. The vaccine candidate (OZG-38.61.3) was then applied in mice by employing the intradermal route, which decreased the requirement of a higher concentration of inactivated virus for proper immunization, unlike most of the classical inactivated vaccine treatments. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 1013 or 1014 viral copy per dose) of OZG-38.61.3 was initially determined in Balb/c mice. This was followed by testing the immunogenicity and protective efficacy of OZG-38.61.3. Human ACE2-encoding transgenic mice were immunized and then infected with a dose of infective SARS-CoV-2 virus for the challenge test. Findings of this study show that vaccinated mice have lower SARS-CoV-2 viral copy number in oropharyngeal specimens along with humoral and cellular immune responses against the SARS-CoV-2, including the neutralizing antibodies similar to those shown in Balb/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.

immunology↗

bioRxiv2020

Preliminary report of preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates, SK-01 version 1 and OZG-3861 version 1

COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice.

immunology↗